bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

6.055 -0.090 (-1.46%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about bioAffinity Technologies, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Traders are paying attention to the gapping stocks in Monday's session. ↗

March 17, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

March 13, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

March 06, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

February 26, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

February 25, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029

January 30, 2025

EQNX::TICKER_START (NASDAQ:INBS),(NASDAQ:CDIO),(NASDAQ:BIAF),(NASDAQ:TRIB),(NASDAQ:SOBR) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Cannabis Death

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

January 22, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029

January 30, 2025

From FN Media Group LLC

Via GlobeNewswire

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

January 13, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

January 10, 2025

Via ACCESSWIRE

Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

December 17, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Set for Continued Expansion in 2025

December 12, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule

December 05, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

November 14, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

November 04, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 01, 2024

Via Benzinga

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung

October 30, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 23, 2024

Via Benzinga

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement

October 21, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 18, 2024

Via Benzinga

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

October 18, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines

October 16, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer

October 10, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

Are Pharma Stocks Harmful To Your Financial Health ? ↗

October 09, 2024

It seems time for the Securities and Exchange Commission to oversee stock advertising and consider a ban, or at least a danger warning label.

Via Talk Markets

bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO

August 23, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test

October 09, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q2 2024 ↗

August 14, 2024

bioAffinity Technologies just reported results for the second quarter of 2024.

Via InvestorPlace

bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales

August 14, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis

September 18, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million

August 05, 2024

From bioAffinity Technologies, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.